PMID- 28375658
OWN - NLM
STAT- MEDLINE
DCOM- 20170417
LR  - 20220311
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 18
IP  - 6
DP  - 2017 Apr
TI  - Empagliflozin/linagliptin single-pill combination therapy for patients with type 
      2 diabetes mellitus.
PG  - 545-549
LID - 10.1080/14656566.2017.1299712 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is typically progressive, with sequential 
      addition of therapies often needed to address increasing hyperglycemia over the 
      disease course. Using treatments in combination may be preferred to sequential 
      addition, as a means of providing a more rapid clinical response and potentially 
      avoiding clinical inertia. In such cases, a single-pill combination can help to 
      reduce pill burden. Although various single-pill combinations of oral 
      glucose-lowering agents are available, empagliflozin/linagliptin was the first 
      approved combination of a sodium glucose co-transporter 2 (SGLT2) inhibitor with 
      a dipeptidyl peptidase 4 (DPP-4) inhibitor in the United States. Areas covered: 
      Two publications of the clinical trial investigating the efficacy and safety of 
      single-pill combinations of empagliflozin/linagliptin in treatment-naive or 
      metformin-treated patients with T2DM (NCT01422876) are reviewed, and their 
      potential impact on clinical practice is discussed. Expert opinion: The study 
      discussed provides evidence for the efficacy and safety of 
      empagliflozin/linagliptin single pills. Addition of an empagliflozin/linagliptin 
      single pill may be considered in patients with inadequate glycemic control on 
      metformin, or as an alternative to first-line treatment with empagliflozin or 
      linagliptin when metformin is not suitable, particularly in patients with very 
      poor glycemic control, or those who need to achieve target more quickly.
FAU - Jain, Rajeev Kumar
AU  - Jain RK
AD  - a Aurora Health Center , Aurora Advanced Healthcare, Inc ., Milwaukee , WI , USA.
LA  - eng
PT  - Journal Article
DEP - 20170404
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 9100L32L2N (Metformin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/*administration & dosage
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Drug Combinations
MH  - Glucosides/*administration & dosage
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents/*administration & dosage/therapeutic use
MH  - Linagliptin/*administration & dosage
MH  - Metformin/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - DPP-4 inhibitors
OT  - SGLT2 inhibitors
OT  - empagliflozin
OT  - linagliptin
OT  - metformin
OT  - phase III clinical trial
OT  - single-pill combination therapy
OT  - type 2 diabetes mellitus
EDAT- 2017/04/05 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/05 06:00
PHST- 2017/04/05 06:00 [pubmed]
PHST- 2017/04/18 06:00 [medline]
PHST- 2017/04/05 06:00 [entrez]
AID - 10.1080/14656566.2017.1299712 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2017 Apr;18(6):545-549. doi: 
      10.1080/14656566.2017.1299712. Epub 2017 Apr 4.